Oxidative stress, inflammation and nutritional status during darbepoetin α treatment in peritoneal dialysis patients

Clinical Nephrology

Volumn 73, Issue 3, 2010, Pages 210-215

  Malgorzewicz, S ^a   Lichodziejewska Niemierko, M ^a   Lizakowski, S ^a   Liberek, T ^a   Lysiak Szydlowska, W ^a   Rutkowski, B ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Darbepoetin; Erythropoetin ; Peritoneal dialysis

Indexed keywords

4 HYDROXYNONENAL; ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; HEMOGLOBIN; INTERLEUKIN 6; IRON; MALONALDEHYDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BIOCHEMISTRY; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMATOCRIT; HEMATOLOGY; HUMAN; INFLAMMATION; LABORATORY TEST; MALE; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PROSPECTIVE STUDY; VOLUNTEER;

EID: 77649303397     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp73210     Document Type: Article

References (22)

1. Agarwal AK, Silver MR, Reed JE et al. An open-label study of darbepoetin α administered once monthly for the maintenance of hemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med. 2006; 260: 577-585.
2. Aguilera A, Bajo MA, Díez JJ, Ruiz-Caravaca ML, Vicenta Cuesta M, Alvarez V, Codoceo R, Selgas R. Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients. Adv Perit Dial 2002; 18: 200-205.
3. Akgul A, Bilgic A, Sezer S, Ozdemir FN, Olcay I, Arat Z, Haberal M. Effect of protein-energy malnutrition on erythropoietin requirement in maintenance hemodialysis patients. Hemodial Int. 2007; 11: 198-203.
4. Andre JL, Deschenes G, Boudailliez B, Broux F, Fischbach M, Gagnadoux MF, Horen B, Lahoche-Manucci A et.al. Darbepoetin, effective treatment of anaemia in pediatric patients with chronic renal failure. Pediatr Nephrol. 2007; 11: 234-235.
5. Barclay L. Functional Data Analysis May Facilitate Study of the Control of Renal Anemia. J Am Soc Nephrol. 2007; 18: 2371-2376.
6. Bistrian BR, McCowen KC, Chan S. Protein - Energy malnutrition in dialysis patients. Am J Kid Dis. 1999; 33: 172-175.
7. Bryl E, Mysliwska J, Debska-Slizien A, Trzonkowski P, Rachon D, Bullo B et al. Recombinant Human Erythropoetin stimulates production of interleukin 2 by whole blood cell cultures of the hemodialysis patients. Artificial Organs. 1999; 23: 809.
8. Cremieux PY, Van Audenrode M, Lefebvre P. The relative dosing of epoetin α and darbepoetin α in chronic kidney disease. Curr Med Res Opin. 2006; 22: 2329-2336.
9. Dumler F. Impact of switching from epoetin to darbepoetin α on anemia management: results in a clinical practice setting. Program and abstracts of the Annual Dialysis Conference; February 18-20, 2007; Denver, Colorado.
10. Kalantar-Zadeh K, Block G, Kelly MP, Schroepfer C, Rodriguez RA, Humphreys MH. Near infra-red interactance for longitudinal assessment of nutrition in dialysis patients. J Ren Nutr. 2001; 11: 23-31.
11. Kopple J. Therapeutic Approaches to Malnutrition in Chronic Dialysis Patients: The Different Modalities of Nutritional Support. Am J Kid Dis. 1999; 33: 180-185.
12. Li WY, Chu TS, Huang JW, Wu MS, Wu KD. Randomized study of darbepoetin α and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.J Formos Med Assoc. 2008; 107: 843-850.
13. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin α at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant. 2003; 18: 362-369.
14. Neves PL, Morgado E, Faisca M et al. Nutritional and inflammatory status influence darbepoetin dose in pre-dialysis elderly patients. Int Urol Nephrol. 2006; 38: 811-813.
15. NKF-DOQI clinical practice guidelines for treatment of anemia of chronic renal failure. Am J Kideney Dis. 2001; 31: 556-558.
16. O'Riordan E., Foley RN. Effects of anaemia on cardiovascular status. Nephrol. Dial. Transpalnt. 2000; 15 (Suppl): 19-211.
17. Pertosa G, Grandaliano G, Gesualdo L, Schena FP. Clinical relevance of cytokine production in hemodialysis. Kidney International. 2000; 58 (Suppl): 104-111.
18. Rutkowski B. Erytropoetyna. Gdansk: MAKmed; 2001.
19. Steiber AL, Kalantar-Zadeh K, Secker D et al. Subjective global assessment in chronic kidney disease: A Review. J Ren Nutr. 2004; 14:191-200.
20. Stenvinkel P, Heimburger O, Lindholm B et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000; 15: 953-960.
21. Theodoridis M, Passadakis P, Kriki P et al. Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients. Perit Dial Int. 2005; 25: 564-569.
22. Toigo G, Aparicio M, Attman PO. et al: Expert working group report on nutrition in adult patients with renal insufficiency (part 1, 2). Clin Nutr. 2000; 19: 197-207; 281-291.